美托洛尔联合曲美他嗪治疗冠心病心力衰竭的效果评价

Evaluation of the Effect of Metoprolol Combined with Trimetazidine in the Treatment of Coronary Heart Disease and Heart Failure

目的刍议对冠心病心力衰竭患者实施美托洛尔联合曲美他嗪治疗的临床价值。方法方便选取198例该院于2015年2月—2019年10月内收治的冠心病心力衰竭患者为研究对象,依据药物差异原则分组,对照组行美托洛尔单药治疗,观察组以对照组为基准,联合曲美他嗪治疗。观察临床疗效、治疗前后心功能、心率、血压、生活质量改善情况。结果①观察组临床疗效96.9%,对照组为89.8%,差异有统计学意义(χ^2=4.034,P<0.05)。②经治疗后观察组LVEDD、LVESD较低、LVEF、6 min步行距离较高,心功能明显较对照组好,差异有统计学意义(t=4.131、4.804、5.749、11.678,P<0.05)。③经治疗后观察组心率较稳定,血压较低,差异有统计学意义(t=5.827、6.104、4.819,P<0.05)。④治疗后观察组躯体功能、社会功能等生活质量各指标评分较高,差异有统计学意义(t=15.442、19.132、26.717、20.141,P<0.05)。结论临床治疗冠心病心力衰竭患者用药,建议采纳美托洛尔联合曲美他嗪治疗,在提高临床疗效、提升心功能、稳定心率、降低血压、改善生活质量方面价值显著。

Objective To discuss the clinical value of metoprolol combined with trimetazidine in patients with coronary heart disease and heart failure.Methods 198 patients with coronary heart disease and heart failure admitted to the hospital from February 2015 to October 2019 were conveniently selected as the research objects,grouped according to the principle of drug difference,and a control group was treated with metoprolol monotherapy.The observation group was treated with trimetazidine based on the control group.Observe the clinical efficacy,heart function,heart rate,blood pressure,and quality of life improvement before and after treatment.Results 1.The clinical efficacy was 96.9%in the observation group and 89.8%in the control group,the difference was statistically significant(χ^2=4.034,P<0.05).2.After treatment,the observation group had lower LVEDD,LVESD,higher LVEF,6 min walking distance,and significantly better cardiac function than the control group,the difference was statistically significant(t=4.131,4.804,5.749,11.678,P<0.05).3.After treatment,the observation group had stable heart rate and lower blood pressure,the difference was statistically significant(t=5.827,6.104,4.819,P<0.05).4.After treatment,the observation group had higher scores of physical function,social function and other quality of life indicators,the difference was statistically significant(t=15.442,19.132,26.717,20.141,P<0.05).Conclusion Metoprolol combined with trimetazidine is recommended for clinical treatment of patients with coronary heart disease and heart failure;it has significant value in improving clinical efficacy,improving heart function,stabilizing heart rate,lowering blood pressure,and improving quality of life.